NICE: Pfizer's Xalkori still not good value for money
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has published final and binding guidance rejecting Pfizer's lung cancer drug Xalkori (crizotinib) for use on the National Health Service. The product does not offer value for money, said Sir Andrew Dillon, NICE's chief executive.